Binosto

Active Ingredient(s): Alendronate Sodium
FDA Approved: * March 12, 2012
Pharm Company: * EFFRX PHARM. SA
Category: Osteoporosis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Binosto Overview

Alendronic acid (INN) or alendronate sodium, sold in the U.S. under the trade name Fosamax among others, is a bisphosphonate drug used for osteoporosis, osteogenesis imperfecta, and several other bone diseases. It is marketed alone as well as in combination with vitamin D. Merck's U.S. patent on alendronate expired in 2008 and the drug is now available as a generic. It is the most widely prescribed bisphosphonate medicine in the United States.[citation needed] Contents 1 M...

Read more Binosto Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Alendronate

Recent Binosto Forums:

Possible Dosages for this and Related Drugs:

NDC Database Records for Binosto: (1 result)

Sorted by National Drug Code

• 0178-0101 Binosto 0.583 mg/ml Oral Solution by Mission Pharmacal Company

Other drugs which contain Alendronate Sodium or a similar ingredient: (4 results)

• ALENDRONATE 16 discussions
• FOSAMAX Alendronate21 discussions
• ALENDRONATE SODIUM + CHOLECALCIFEROL 1 discussion
• FOSAMAX PLUS D Alendronate Sodium + Cholecalciferol